Thanks Flipper, that had to be an unusual buyout, but I suppose if shareholders accept the fact that a company is greatly undervalued anything is possible. Even at 5X we'd need to reach at least a $4 share price to get they minimum I've gathered LP would take. That's a price we could easily reach if news is generally good this year, I'd be very surprised if it could get a $20 a share offer.
If we achieved the right media attention for what our vaccine will do when combined with Poly-ICLC and/or Keytruda, I'd not be surprised it we got a huge spike up to $20 or more, I don't see it being sustained there, however, if either a partnership or buyout was established during such a spike, almost any price could be sustained as it would be validated by the offer.
I've got to believe that at some point the company will go for major media attention. In the time I've been a shareholder I cannot remember a single time when LP has spoken at a brokerage or Institutional conference, or even sponsored a presentation with an organization like BIO. Once news starts coming out on DCVax-L with other therapeutics extending 5 year survival to 50% or greater I believe that LP will very routinely be invited to discuss the company, and of course our share price will be much higher. I don't know for certain when this will happen, but I believe it could come with the UK approval, so it may not be that many months away.
Gary
Bullish
Market Data 
Markets 
AI
